Edition:
United States

Teva Pharmaceutical Industries Ltd (TEVA.N)

TEVA.N on New York Stock Exchange

22.25USD
16 Nov 2018
Change (% chg)

$-0.37 (-1.64%)
Prev Close
$22.62
Open
$22.49
Day's High
$22.82
Day's Low
$22.13
Volume
1,196,549
Avg. Vol
2,389,304
52-wk High
$25.96
52-wk Low
$12.40

Select another date:

Thu, Nov 1 2018

Photo

Teva Pharm raises 2018 profit outlook, sees strong migraine drug launch

TEL AVIV Teva Pharmaceutical Industries raised its 2018 earnings outlook, said it was seeing "a very strong launch" for its long-awaited migraine treatment Ajovy and expects to launch generic EpiPen in the fourth quarter.

Teva Pharm Q3 profit tops estimates, raises 2018 profit forecast

TEL AVIV, Nov 1 Israel's heavily indebted Teva Pharmaceutical Industries reported a smaller-than-expected drop in third-quarter profit on Thursday and raised its earnings outlook for 2018.

REFILE-BRIEF-Harbin Pharmaceutical Signs Agreement With Israel's Teva Pharmaceutical Industries

* SAYS IT SIGNS AUTHORIZATION AND DISTRIBUTION AGREEMENT WITH ISRAEL'S TEVA PHARMACEUTICAL INDUSTRIES, EXPECTS INVESTMENT OF ABOUT 160 MILLION YUAN Source text in Chinese: https://bit.ly/2PdGwJL Further company coverage: (Reporting by Hong Kong newsroom)

Brazilian drugmaker EMS interested in Europe's Medis -paper

SAO PAULO, Oct 2 Brazilian drugmaker EMS is interested in acquiring Iceland-based generic drugmaker Medis, put on sale by Israel's Teva Pharmaceutical Industries Ltd a year ago, Brazilian newspaper O Estado de S. Paulo reported on Tuesday.

Lilly defeats Teva patent lawsuits over migraine drug

A federal judge on Thursday dismissed a pair of patent infringement lawsuits by Teva Pharmaceutical Industries Ltd that sought to block Eli Lilly and Co from bringing its migraine drug Emgality to market in the United States.

U.S. judge dismisses Teva lawsuits against Lilly on migraine drug

BOSTON A federal judge on Thursday dismissed a pair of patent infringement lawsuits by Teva Pharmaceutical Industries Ltd that sought to block Eli Lilly and Co from bringing its migraine drug Emgality to market in the United States.

U.S. judge dismisses Teva lawsuits against Lilly on migraine drug

BOSTON, Sept 27 A federal judge on Thursday dismissed a pair of patent infringement lawsuits by Teva Pharmaceutical Industries Ltd that sought to block Eli Lilly and Co from bringing its migraine drug Emgality to market in the United States.

UnitedHealth must honor $125 mln settlement its outside counsel cinched with Teva - judge

UnitedHealth Group is bound by a $125 million settlement between Teva Pharmaceutical Industries and several insurance companies resolving claims that Cephalon Inc, later bought by Teva, suppressed competition for its wakefulness drug Provigil, a federal judge in Pennsylvania has ruled.

U.S. regulator approves Teva migraine drug, shares rise

Shares of Israeli drugmaker Teva Pharmaceutical Industries rose over 5 percent in after-hours trading on Friday after the U.S. Food and Drug Administration (FDA) approved the company's new migraine treatment, a drug Teva has been banking on to help revive its fortunes.

UPDATE 2-U.S. regulator approves Teva migraine drug, shares rise

Sept 14 Shares of Israeli drugmaker Teva Pharmaceutical Industries rose over 5 percent in after-hours trading on Friday after the U.S. Food and Drug Administration (FDA) approved the company's new migraine treatment, a drug Teva has been banking on to help revive its fortunes.

Select another date: